查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
精密精神医学的全球市场 - 产业规模，占有率，趋势，机会，预测:各生物标记，各样品，各技术，各用途，各终端用户，各企业，各地区(2017年～2027年)
市场调查报告书
商品编码
1152254

精密精神医学的全球市场 - 产业规模，占有率，趋势，机会，预测:各生物标记，各样品，各技术，各用途，各终端用户，各企业，各地区(2017年～2027年)

Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Biomarkers, By Sample, By Technology, By Application, By End User, By Company and By Region
出版日期: | 出版商: TechSci Research | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球精密精神医学的市场规模，在预测期间内的2023年～2027年预计达成惊人的成长。

市场成长的主要原因，是精神疾病发病率的上升和技术进步，推动全球市场成长。支撑市场成长的其他因素，是认识度的提高，投资扩大，人口增加，生活方式的变化，序列成本低，无机成长策略的采用增加政府对医疗基础设施的，的支援等。还有进行精神疾病发病和征兆相关的基因、蛋白质体学分析的研究人员对先进分子诊断技术高的引进率，也是推动市场成长的主要原因。

本报告提供全球精密精神医学市场相关调查分析，各市场区隔、各地区的市场规模、占有率预测，市场动态，企业简介等系统性资讯。

目录

第1章 产品概要

第2章 调查手法

第3章 摘要整理

第4章 COVID-19对全球精密精神医学市场的影响

第5章 VOC(客户的迴响)

第6章 全球精密精神医学市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各生物标记(遗传基因和蛋白质)
    • 各样品(血液为基础和血液为基础以外)
    • 各技术(定序，聚合酵素链锁反应，微阵列，免疫测量，其他)
    • 各用途(阿兹海默症，帕金森氏症，自闭症，忧郁症，其他)
    • 各终端用户(医院、诊所，学术、调查机关，其他)
    • 各企业(2021年)
    • 各地区
  • 产品市场地图

第7章 北美的精密精神医学市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各生物标记
    • 各样品
    • 各技术
    • 各用途
    • 各终端用户
    • 各国
  • 北美:各国分析
    • 美国
    • 墨西哥
    • 加拿大

第8章 欧洲的精密精神医学市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各生物标记
    • 各样品
    • 各技术
    • 各用途
    • 各终端用户
    • 各国
  • 欧洲:各国分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第9章 亚太地区的精密精神医学市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各生物标记
    • 各样品
    • 各技术
    • 各用途
    • 各终端用户
    • 各国
  • 亚太地区:各国分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第10章 南美的精密精神医学市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各生物标记
    • 各样品
    • 各技术
    • 各用途
    • 各终端用户
    • 各国
  • 南美:各国分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第11章 中东、非洲的精密精神医学市场展望

  • 市场规模与预测
    • 各金额
  • 市场占有率与预测
    • 各生物标记
    • 各样品
    • 各技术
    • 各用途
    • 各终端用户
    • 各国
  • MEA:各国分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 埃及
    • 土耳其

第12章 市场动态

  • 促进因素
  • 课题

第13章 市场趋势与开发

第14章 竞争情形

  • Altimate Healthcare
  • PsyProtix, Inc
  • Cerebral-Alto Nanoscience
  • Precision Psychiatric Services, Inc
  • Tempus Labs, Inc.
  • Curis AI Inc.

第15章 策略性建议

简介目录
Product Code: 12983

The global precision psychiatry market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include rise in incidences of mental health and technological advancements, which are bolstering the market growth, globally. Precision psychiatry is new field within precision medicine, which seeks to detect and capitalize on individual differences in biology, environment, lifestyle, and social determinants of health to improve mental health prevention, diagnosis, and treatment. The other factors supporting the market's growth are increasing awareness, growing investments, increase in population, changing lifestyle, decreasing cost of sequencing, increasing adoption of inorganic growth strategies and support from governments for healthcare infrastructure. Also, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis associated to the onset and manifestation of psychiatric illnesses are some of the key factors that are projected to bolster the market growth.

Increase in Prevalence of Mental Disorders

Over the past few years, rise in number of people suffering from mild or severe depressive disorders is seen. These mental illness or disorders are basically caused due to chemical, genetic, and anatomical conditions, or psychological origins such as trauma. Thus, to seek better lives for those suffering from mental illness, precision psychiatry is much required, which attributes to the growth of the market, globally. For instance, according to the National Institute of Mental Health, around one in every five U.S. adults suffer from mental illness. Also, in 2020, 25.8% of females were suffering from mental illness.

Increasing Adoption of Inorganic Growth Strategies

Increasing inorganic growth strategies by key players are expected to drive the global precision psychiatry market growth during the forecast period. For instance, in 2021, Alto Neuroscience announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. Similarly, in 2021, Atai Life Sciences, a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix, which is a precision psychiatry company.

Increased demand for Genomics as precision psychiatry

From past few years, genomic technologies have advanced the understanding of neuropsychiatric disorders. Genomics plays a significant part in the diagnosis of several genetic disorders. It has ample scope in precision psychiatry as it can advocate medical management constructed on the genetic face of a person with the help of clinical data and AI. It incorporates DNA sequencing methods, recombinant DNA, and bioinformatics for sequencing, assembling, and analyzing the structure and functions of genomes. Many severe mental illnesses, such as schizophrenia and bipolar disorder, are highly inherited, and have a complex pattern of inheritance. These diseases can be identified by using sequencing technology, which evaluates the rare genetic variants. With the use of sequencing technology, psychiatry can ultimately reshape by predicting disease risk and lead to better understanding of aetiology, prognosis, or treatment response. Moreover, the decrease in cost of sequencing is also a key factor to increase the growth of the market.

Market Segmentation

The global precision psychiatry market is segmented into biomarkers, sample, technology, application, end user, and company. Based on biomarker, the market is divided into genetic and protein. Based on sample, the market is divided into blood-based and non-blood-based. Based on non-blood-based, the market is further divided into saliva, urine, cerebral spinal fluid, and others. Based on technology, the market is divided into sequencing, polymerase chain reaction, microarray, immunoassay, and others. Based on application, the market is divided into Alzheimer's disease, Parkinson's disease, autism, depression, and others. Based on end user, the market is divided into hospital & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rise in incidences of mental illness in the country.

Market Players

Altimate Healthcare, PsyProtix, Inc, Cerebral-Alto Nanoscience, Precision Psychiatric Services, Inc, Tempus Labs, Inc., and Curis AI Inc. are some of the leading companies operating in the market.

Report Scope:

In this report, global precision psychiatry market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Precision Psychiatry Market, By Biomarker:

  • Genetic
  • Protein

Precision Psychiatry Market, By Sample:

  • Blood Based
  • Non-Blood-Based
    • Saliva
    • Urine
    • Cerebral Spinal Fluid
    • Others
    • Precision Psychiatry Market, By Technology:
  • Sequencing
  • Polymerase Chain Reaction
  • Microarray
  • Immunoassay
  • Others

Precision Psychiatry Market, By Application:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Autism
  • Depression
  • Others

Precision Psychiatry Market, By End User:

  • Hospital & Clinics
  • Academic & Research Institutions
  • Others

Precision Psychiatry Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in precision psychiatry market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Precision Psychiatry Market

5. Voice of Customer

6. Global Precision Psychiatry Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Biomarkers (Genetic v/s Protein)
    • 6.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 6.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 6.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 6.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 6.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 6.2.6. By Company (2021)
    • 6.2.7. By Region
  • 6.3. Product Market Map

7. North America Precision Psychiatry Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Biomarkers (Genetic v/s Protein)
    • 7.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 7.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 7.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 7.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 7.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Precision Psychiatry Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Biomarker
        • 7.3.1.2.2. By Sample
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. Mexico Precision Psychiatry Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Biomarker
        • 7.3.2.2.2. By Sample
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Canada Precision Psychiatry Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Biomarker
        • 7.3.3.2.2. By Sample
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User

8. Europe Precision Psychiatry Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Biomarkers (Genetic v/s Protein)
    • 8.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 8.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 8.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 8.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 8.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Precision Psychiatry Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Biomarker
        • 8.3.1.2.2. By Sample
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Germany Precision Psychiatry Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Biomarker
        • 8.3.2.2.2. By Sample
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. United Kingdom Precision Psychiatry Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Biomarker
        • 8.3.3.2.2. By Sample
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. Italy Precision Psychiatry Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Biomarker
        • 8.3.4.2.2. By Sample
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Spain Precision Psychiatry Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Biomarker
        • 8.3.5.2.2. By Sample
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Asia-Pacific Precision Psychiatry Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Biomarkers (Genetic v/s Protein)
    • 9.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 9.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 9.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 9.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 9.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Precision Psychiatry Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Biomarker
        • 9.3.1.2.2. By Sample
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. India Precision Psychiatry Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Biomarker
        • 9.3.2.2.2. By Sample
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Korea Precision Psychiatry Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Biomarker
        • 9.3.3.2.2. By Sample
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User
    • 9.3.4. Japan Precision Psychiatry Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Biomarker
        • 9.3.4.2.2. By Sample
        • 9.3.4.2.3. By Technology
        • 9.3.4.2.4. By Application
        • 9.3.4.2.5. By End User
    • 9.3.5. Australia Precision Psychiatry Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Biomarker
        • 9.3.5.2.2. By Sample
        • 9.3.5.2.3. By Technology
        • 9.3.5.2.4. By Application
        • 9.3.5.2.5. By End User

10. South America Precision Psychiatry Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Biomarkers (Genetic v/s Protein)
    • 10.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 10.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 10.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 10.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 10.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Precision Psychiatry Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Biomarker
        • 10.3.1.2.2. By Sample
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Argentina Precision Psychiatry Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Biomarker
        • 10.3.2.2.2. By Sample
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Colombia Precision Psychiatry Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Biomarker
        • 10.3.3.2.2. By Sample
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Middle East and Africa Precision Psychiatry Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Biomarkers (Genetic v/s Protein)
    • 11.2.2. By Sample (Blood Based v/s Non-Blood-Based)
      • 11.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
    • 11.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
    • 11.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
    • 11.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Precision Psychiatry Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Biomarker
        • 11.3.1.2.2. By Sample
        • 11.3.1.2.3. By Technology
        • 11.3.1.2.4. By Application
        • 11.3.1.2.5. By End User
    • 11.3.2. Saudi Arabia Precision Psychiatry Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Biomarker
        • 11.3.2.2.2. By Sample
        • 11.3.2.2.3. By Technology
        • 11.3.2.2.4. By Application
        • 11.3.2.2.5. By End User
    • 11.3.3. UAE Precision Psychiatry Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Biomarker
        • 11.3.3.2.2. By Sample
        • 11.3.3.2.3. By Technology
        • 11.3.3.2.4. By Application
        • 11.3.3.2.5. By End User
    • 11.3.4. Egypt Precision Psychiatry Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Biomarker
        • 11.3.4.2.2. By Sample
        • 11.3.4.2.3. By Technology
        • 11.3.4.2.4. By Application
        • 11.3.4.2.5. By End User
    • 11.3.5. Turkey Precision Psychiatry Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Biomarker
        • 11.3.5.2.2. By Sample
        • 11.3.5.2.3. By Technology
        • 11.3.5.2.4. By Application
        • 11.3.5.2.5. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Altimate Healthcare
  • 14.2. PsyProtix, Inc
  • 14.3. Cerebral-Alto Nanoscience
  • 14.4. Precision Psychiatric Services, Inc
  • 14.5. Tempus Labs, Inc.
  • 14.6. Curis AI Inc.

15. Strategic Recommendations